NU
NURPF.US Neuren Pharmaceuticals Limited
- Market cap
- USD 1.74B
- P/E
- 137.6x
- P/B
- 7.65x
- ROE
- 5.8%
- Dividend yield
- 1.52%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is NURPF.US undervalued?
Graham numberThe Graham number of Neuren Pharmaceuticals Limited cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Neuren Pharmaceuticals Limited fundamental analysis
No fundamental analysis for Neuren Pharmaceuticals Limited yet.
Neuren Pharmaceuticals Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial…
Full company profileNeuren Pharmaceuticals Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Neuren Pharmaceuticals Limited annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.15M | 631K | 14.0M | 495K | 717K | 3.20M | 14.6M | 232M | 217M | 64.6M | 132M |
| Gross Profit | 3.07M | 553K | 7.89M | 491K | 711K | 3.19M | 14.5M | 205M | 184M | 64.6M | 132M |
| Operating Income | -15.2M | -6.70M | 5.82M | -11.6M | -16.6M | -17.7M | -1.60M | 172M | 146M | 22.0M | 10.9M |
| EBITDA | -13.8M | -5.99M | 5.37M | -11.3M | -8.80M | -8.23M | -722K | 199M | 179M | 22.0M | 10.9M |
| Net Income | -12.0M | 3.29M | 3.07M | -10.8M | -9.19M | -7.79M | 184K | 157M | 142M | 30.4M | 19.4M |
| EPS | -2.84 | 0.04 | 0.03 | -0.11 | -0.09 | -0.07 | 0.00 | 1.20 | 1.09 | 0.23 | 0.15 |
| Balance Sheet | |||||||||||
| Total Assets | 6.21M | 17.9M | 26.6M | 14.4M | 25.0M | 40.1M | 43.3M | 248M | 410M | 343M | 340M |
| Total Liabilities | 2.03M | 1.58M | 1.97M | 559K | 753K | 803K | 1.68M | 42.8M | 45.8M | 4.40M | 7.23M |
| Shareholders' Equity | 4.18M | 16.4M | 24.7M | 13.8M | 24.2M | 39.3M | 41.6M | 205M | 364M | 338M | 333M |
| Cash & Short-term Investments | 5.05M | 4.71M | 23.6M | 13.8M | 24.2M | 36.8M | 40.2M | 229M | 222M | 296M | 286M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -12.4M | -5.59M | 6.41M | -11.7M | -8.08M | -9.97M | 3.60M | 185M | -11.3M | 125M | 32.0M |
| Capital Expenditure | 10.0K | 12.0K | 12.0K | 12.0K | 6.00K | 10.0K | 19.0K | 40.0K | 10.0K | 37.0K | 32.0K |
| Free Cash Flow | -12.4M | -5.59M | 6.41M | -11.7M | -8.08M | -9.98M | 3.58M | 185M | -11.3M | 125M | 31.9M |
| Ratios | |||||||||||
| ROE | -287.2% | 20.1% | 12.5% | -78.1% | -38.0% | -19.9% | 0.4% | 76.5% | 39.0% | 9.0% | 5.8% |
| ROA | -193.5% | 18.3% | 11.5% | -75.1% | -36.8% | -19.5% | 0.4% | 63.3% | 34.7% | 8.9% | 5.7% |
| Net Profit Margin | -381.4% | 521.1% | 22.0% | -2,185.1% | -1,282.1% | -243.8% | 1.3% | 67.7% | 65.5% | 47.1% | 14.6% |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.00x | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Neuren Pharmaceuticals Limited dividends
- Dividend yield
- 1.52%
- Forward dividend
- 0.21 USD
- Payout ratio
- -
- Ex-dividend date
- Sep 15, 2026
Last stock split: 1:20 on Nov 21, 2017.
Who owns Neuren Pharmaceuticals Limited
- Insiders 13.34%
- Institutions 23.11%
- Public & others 63.55%
- Shares outstanding 127M
- Free float 110M
Neuren Pharmaceuticals Limited company profile
- Company name
- Neuren Pharmaceuticals Limited
- Ticker
- NURPF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 117 Camberwell Road, Hawthorn East, VIC, Australia, 3123
- Phone
- 61 3 9092 0480
- Website
- neurenpharma.com
About Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in preclinical trial stage for the treatment of Prader-Willi syndrome, Hypoxic Ischemic Encephalopathy, and SYNGAP1. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
Neuren Pharmaceuticals Limited management
6- Ms. Lauren Frazer C.A.CFO & Company Secretary
- Dr. Clive Blower BSc (Hons), Ph.D.Chief Operations Officer
- Mr. Lawrence Glass BA (Biology)Chief Science Officer
- Mr. Gerry ZhaoChief Business Officer
- Dr. Liza A. Squires M.D.Chief Medical Officer
- Mr. Daryl Dekarske M.P.H.Chief Regulatory Officer